Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa, Multi-center, Single-Arm, Open-Label Study to Evaluate the Efficacy of ALMB-0168 in Solid Tumor Patients With Bone Metastatic Whose Prior Standard Treatment Have Failed

NCT06416358 is registered in ClinicalTrials.gov with AlaMab Therapeutics (Shanghai) Inc. as lead sponsor.

NCT NCT06416358
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06416358 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa, Multi-center, Single-Arm, Open-Label Study to Evaluate the Efficacy of ALMB-0168 in Solid Tumor Patients With Bone Metastatic Whose Prior Standard Treatment Have Failed
Lead sponsor
AlaMab Therapeutics (Shanghai) Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
May 31, 2024
Completion date
December 31, 2026
Enrollment
144 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors with bone only metastasis